{
    "title": "114_s1406",
    "content": "The Act may be cited as the \"Saving Access to Compounded Medications for Special Needs Patients Act\". Pharmacy compounding is addressed in the Act. Section 503A of the Federal Food, Drug, and Cosmetic Act is amended to allow drug products to be compounded and distributed to practitioners for patient treatment, with specific requirements for compounding by licensed pharmacists or physicians. Section 503A of the Federal Food, Drug, and Cosmetic Act is amended to allow drug products to be compounded and distributed to practitioners for patient treatment, with specific requirements for compounding by licensed pharmacists or physicians, including compliance with USP standards for compounding. The amendment to Section 503A allows drug products to be compounded for patients of practitioners under specific requirements, including compliance with USP standards. The amendment to Section 503A allows compounded drug products to be distributed outside the state under specific conditions, either through a memorandum of understanding with the Secretary or by meeting certain criteria if no such agreement is in place. The amendment to Section 503A allows compounded drug products to be distributed outside the state under specific conditions, either through a memorandum of understanding with the Secretary or by meeting certain criteria if no such agreement is in place. The limitation on memorandum of understanding states that it shall not create an unfunded mandate on a State. The amendment to Section 503A expands the definition of compounding and distribution of compounded drug products, excluding certain acts from compounding and dispensing for individual patients."
}